January 10, 2012 -- Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing for the pharmaceutical and biotech industry, announced today that new business partnerships secured during the fourth quarter will generate significant revenue for the company. Norwich has been expanding its development and pilot scale capabilities throughout 2011 in order to meet the growing market demand for comprehensive solutions that include scale-up and commercial manufacturing.
“Norwich is intensely focused to provide an experience for our customers that improves time efficiency and ensures quality,” said Terry Novak, president of Norwich Pharmaceuticals. “We continue to strategically invest in unique technical capabilities, and our strength with global distribution is being recognized as an advantage for several new customers.”
The new business partnerships announced today include five new projects that could add more than 500 million units to Norwich commercial production during the next three years with finished product being distributed in both the U.S. and Europe.
About Norwich Pharmaceuticals
Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com for additional information.
